

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Multiple Technology Appraisal (MTA)

#### Dexamethasone intravitreal implant, sirolimus intravitreal injection and adalimumab for treating non-infectious uveitis [ID763]

#### Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Companies</u></p> <ul style="list-style-type: none"> <li>• Santen (sirolimus intravitreal injection)</li> <li>• Allergan (dexamethasone intravitreal implant)</li> <li>• AbbVie (adalimumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Blind People</li> <li>• Behcets Syndrome Society</li> <li>• Birdshot Uveitis Society</li> <li>• Eyecare Trust</li> <li>• Fight for Sight</li> <li>• Muslim Council of Britain</li> <li>• National Federation of the Blind of the UK</li> <li>• Olivia's Vision</li> <li>• OBAC</li> <li>• Royal National Institute of Blind People (RNIB)</li> <li>• SeeAbility</li> <li>• Sense</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thomas Pocklington Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Optometrists</li> <li>• British and Eire Association of Vitreoretinal Surgeons British Diabetic</li> <li>• British Geriatrics Society</li> <li>• British and Irish Orthoptic Society</li> <li>• British Ophthalmic Anaesthesia Society (BOAS)</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Uveitis Information Group (Scotland)</li> <li>• Wales Council for the Blind</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (methotrexate, mycophenolate mofetil, tacrolimus)</li> <li>• Allergan (azathioprine, mycophenolate mofetil, oral prednisolone, azathioprine, mycophenolate mofetil, oral prednisolone)</li> <li>• Alimera Sciences (fluocinolone acetonide intravitreal implant)</li> <li>• Alkopharma (chlorambucil)</li> <li>• AMCo (methotrexate, injectable prednisolone)</li> <li>• Aspen Pharma Trading (azathioprine, chlorambucil, oral &amp; injectable)</li> </ul>

National Institute for Health and Care Excellence  
 Provisional Matrix for the multiple technology appraisal of dexamethasone intravitreal implant, sirolimus intravitreal injection and adalimumab for treating non-infectious uveitis [ID763]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• College of Optometrists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Ophthalmologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Bromley CCG</li> <li>• NHS England</li> <li>• NHS North Lincolnshire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>dexamethasone)</li> <li>• Astellas (tacrolimus)</li> <li>• Auden McKenzie (oral dexamethasone, oral prednisolone)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Beacon Pharmaceuticals (injectable prednisolone)</li> <li>• Boston Healthcare (oral prednisolone)</li> <li>• Cardinal Health Martindale Products (oral dexamethasone)</li> <li>• Celltrion Healthcare/Napp Pharmaceuticals (infliximab biosimilar)</li> <li>• Chemidex Pharma (oral dexamethasone)</li> <li>• Colorama Pharmaceuticals (ciclosporin, mycophenolate mofetil)</li> <li>• Cubic Pharmaceuticals (ciclosporin, mycophenolate mofetil)</li> <li>• DE Pharmaceuticals (azathioprine, ciclosporin, oral dexamethasone, methotrexate, mycophenolate mofetil, injectable prednisolone)</li> <li>• Dexcel (ciclosporin, tacrolimus)</li> <li>• Ennogen Pharma (azathioprine, ciclosporin)</li> <li>• E.R. Squibb &amp; Sons (triamcinolone acetone injectable suspension)</li> <li>• Ethigen (ciclosporin)</li> <li>• Hameln Pharmaceuticals (injectable dexamethasone, methotrexate)</li> <li>• Hospira UK (infliximab biosimilar, injectable dexamethasone, methotrexate)</li> <li>• Icarus Pharmaceuticals (ciclosporin, mycophenolate mofetil)</li> <li>• Medac (methotrexate)</li> <li>• Merck Sharp &amp; Dohme (infliximab, oral dexamethasone)</li> <li>• Mylan UK (ciclosporin, mycophenolate mofetil, tacrolimus)</li> <li>• Niche Pharma (ciclosporin, mycophenolate mofetil)</li> <li>• Novartis (ciclosporin, mycophenolate mofetil)</li> </ul>

National Institute for Health and Care Excellence  
Provisional Matrix for the multiple technology appraisal of dexamethasone intravitreal implant, sirolimus intravitreal injection and adalimumab for treating non-infectious uveitis [ID763]

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Orion Pharma (methotrexate)</li> <li>• Pfizer (cyclophosphamide, methotrexate, injectable prednisolone)</li> <li>• Roche (mycophenolate mofetil)</li> <li>• Rosemont Pharmaceuticals Ltd (oral dexamethasone)</li> <li>• Sandoz (methotrexate, mycophenolate mofetil, tacrolimus)</li> <li>• Teva UK (azathioprine, ciclosporin, cyclophosphamide, methotrexate, mycophenolate mofetil, oral prednisolone, tacrolimus)</li> <li>• Wockhardt (methotrexate, mycophenolate mofetil, oral prednisolone)</li> <li>• Zentiva UK (mycophenolate mofetil, oral prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Council for Prevention of Blindness</li> <li>• Cochrane Eyes and Vision Group</li> <li>• Eye Hope</li> <li>• Institute of Ophthalmology, University College London</li> <li>• International Uveitis Study Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Eye Research Centre</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

National Institute for Health and Care Excellence  
 Provisional Matrix for the multiple technology appraisal of dexamethasone intravitreal implant, sirolimus intravitreal injection and adalimumab for treating non-infectious uveitis [ID763]

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that manufacture comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.